These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
545 related articles for article (PubMed ID: 26603945)
1. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Meulendijks D; Henricks LM; Sonke GS; Deenen MJ; Froehlich TK; Amstutz U; Largiadèr CR; Jennings BA; Marinaki AM; Sanderson JD; Kleibl Z; Kleiblova P; Schwab M; Zanger UM; Palles C; Tomlinson I; Gross E; van Kuilenburg AB; Punt CJ; Koopman M; Beijnen JH; Cats A; Schellens JH Lancet Oncol; 2015 Dec; 16(16):1639-50. PubMed ID: 26603945 [TBL] [Abstract][Full Text] [Related]
2. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537 [TBL] [Abstract][Full Text] [Related]
3. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Del Re M; Cinieri S; Michelucci A; Salvadori S; Loupakis F; Schirripa M; Cremolini C; Crucitta S; Barbara C; Di Leo A; Latiano TP; Pietrantonio F; Di Donato S; Simi P; Passardi A; De Braud F; Altavilla G; Zamagni C; Bordonaro R; Butera A; Maiello E; Pinto C; Falcone A; Mazzotti V; Morganti R; Danesi R Pharmacogenomics J; 2019 Dec; 19(6):556-563. PubMed ID: 30723313 [TBL] [Abstract][Full Text] [Related]
4. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765 [TBL] [Abstract][Full Text] [Related]
6. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087 [TBL] [Abstract][Full Text] [Related]
7. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre. Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114 [TBL] [Abstract][Full Text] [Related]
8. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; van Werkhoven E; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM Eur J Cancer; 2019 Jan; 107():60-67. PubMed ID: 30544060 [TBL] [Abstract][Full Text] [Related]
9. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Froehlich TK; Amstutz U; Aebi S; Joerger M; Largiadèr CR Int J Cancer; 2015 Feb; 136(3):730-9. PubMed ID: 24923815 [TBL] [Abstract][Full Text] [Related]
10. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(14):1-186. PubMed ID: 34484488 [TBL] [Abstract][Full Text] [Related]
11. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine. García-González X; Kaczmarczyk B; Abarca-Zabalía J; Thomas F; García-Alfonso P; Robles L; Pachón V; Vaz Á; Salvador-Martín S; Sanjurjo-Sáez M; López-Fernández LA Cancer Chemother Pharmacol; 2020 Jul; 86(1):45-54. PubMed ID: 32529295 [TBL] [Abstract][Full Text] [Related]
12. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102 [TBL] [Abstract][Full Text] [Related]
13. Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD. Knikman JE; Zhai Q; Lunenburg CATC; Henricks LM; Böhringer S; van der Lee M; de Man FM; Offer SM; Shrestha S; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; van Schaik RHN; Gelderblom H; Mathijssen RHJ; Schellens JHM; Cats A; Guchelaar HJ; Swen JJ Genome Med; 2024 Aug; 16(1):101. PubMed ID: 39148102 [TBL] [Abstract][Full Text] [Related]
14. Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype. Medwid S; Wigle TJ; Kim RB Cancer Chemother Pharmacol; 2023 Jan; 91(1):97-102. PubMed ID: 36357798 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Loganayagam A; Arenas Hernandez M; Corrigan A; Fairbanks L; Lewis CM; Harper P; Maisey N; Ross P; Sanderson JD; Marinaki AM Br J Cancer; 2013 Jun; 108(12):2505-15. PubMed ID: 23736036 [TBL] [Abstract][Full Text] [Related]
16. Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis. Sharma BB; Rai K; Blunt H; Zhao W; Tosteson TD; Brooks GA Oncologist; 2021 Dec; 26(12):1008-1016. PubMed ID: 34506675 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis. de Moraes FCA; de Almeida Barbosa AB; Sano VKT; Kelly FA; Burbano RMR BMC Cancer; 2024 Sep; 24(1):1210. PubMed ID: 39350200 [TBL] [Abstract][Full Text] [Related]
18. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401 [TBL] [Abstract][Full Text] [Related]
19. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. Meulendijks D; Henricks LM; Amstutz U; Froehlich TK; Largiadèr CR; Beijnen JH; de Boer A; Deenen MJ; Cats A; Schellens JH Int J Cancer; 2016 Jun; 138(11):2752-61. PubMed ID: 26804235 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer. Brooks GA; Tapp S; Daly AT; Busam JA; Tosteson ANA Clin Colorectal Cancer; 2022 Sep; 21(3):e189-e195. PubMed ID: 35668003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]